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High CIP2A levels correlate with an antiapoptotic phenotype
that can be overcome by targeting BCL-XL in chronic myeloid
leukemia
CM Lucas1, M Milani1, M Butterworth1, N Carmell1, LJ Scott1, RE Clark1, GM Cohen1,2 and S Varadarajan1,2
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a predictive biomarker of disease progression in many malignancies,
including imatinib-treated chronic myeloid leukemia (CML). Although high CIP2A levels correlate with disease progression in CML,
the underlying molecular mechanisms remain elusive. In a screen of diagnostic chronic phase samples from patients with high
and low CIP2A protein levels, high CIP2A levels correlate with an antiapoptotic phenotype, characterized by downregulation of
proapoptotic BCL-2 family members, including BIM, PUMA and HRK, and upregulation of the antiapoptotic protein BCL-XL. These
results suggest that the poor prognosis of patients with high CIP2A levels is due to an antiapoptotic phenotype. Disrupting this
antiapoptotic phenotype by inhibition of BCL-XL via RNA interference or A-1331852, a novel, potent and BCL-XL-selective inhibitor,
resulted in extensive apoptosis either alone or in combination with imatinib, dasatinib or nilotinib, both in cell lines and in primary
CD34+ cells from patients with high levels of CIP2A. These results demonstrate that BCL-XL is the major antiapoptotic survival
protein and may be a novel therapeutic target in CML.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a malignant disease of a
primitive hematopoietic cell, characterized by a reciprocal
translocation between chromosomes 9 and 22 and creates the
fusion gene BCR-ABL1, which is a deregulated tyrosine kinase that
drives the leukemia.1 CML treatment has been signiﬁcantly
improved by the tyrosine kinase inhibitor (TKI) imatinib, but some
patients will eventually fail imatinib treatment and without a
change in therapy, a signiﬁcant proportion will progress towards
blast crisis (BC), which is usually rapidly fatal.2,3 The kinase activity
of BCR-ABL is opposed by cellular phosphatases, such as protein
phosphatase 2A (PP2A), which is impaired in several malignancies.
PP2A plays an important role in regulating cell proliferation,
differentiation and apoptosis. In CML, PP2A is inhibited by SET4
and cancerous inhibitor of PP2A (CIP2A).5 CIP2A inhibits PP2A
activity and functions by preventing PP2A-driven dephosphoryla-
tion and stabilization of c-Myc.6–8 CIP2A is a strong prospective
predictor of subsequent development of BC in imatinib-treated
CML patients,5 although the underlying mechanisms remain
unclear.
Apoptosis induction is tightly regulated by the BCL-2 family of
proteins, which comprise several antiapoptotic members, such as
BCL-2, BCL-XL, MCL-1, BCL-w and BFL-1, together with proapopto-
tic molecules, such as the multidomain effectors BAX and BAK, as
well as the BH3-only proteins, including the activators BIM,
BID and PUMA, and sensitizers NOXA, HRK, BIK, BMF and BAD.9,10
The BH3-only members can either be promiscuous or selective
with respect to binding their antiapoptotic counterparts.
The activators bind all antiapoptotic BCL-2 family members,
whereas the sensitizers NOXA and HRK are more selective in
binding MCL-1 and BCL-XL, respectively.
11 BCR-ABL modulates the
expression levels and/or the phosphorylation status of several
BCL-2 family members, thus exerting important regulatory effects
on apoptosis.12–15 Furthermore, recent reports suggest important
roles for several antiapoptotic BCL-2 family members in CML
disease progression.16–20 Elevated levels of these proteins in
several cancers make them promising targets for drug therapy.
Small-molecule inhibitors targeting speciﬁc members of the BCL-2
family, such as navitoclax/ABT-263 (BCL-2, BCL-XL and BCL-w-
speciﬁc) and venetoclax/ABT-199 (BCL-2-speciﬁc) are in clinical
trials for several lymphoid malignancies.21,22 Recently, selective
inhibitors of BCL-XL (A-1331852) and MCL-1 (A-1210477) have
been synthesized.23,24 These inhibitors target the antiapoptotic
BCL-2 family members, displacing their sequestered proapoptotic
counterparts, thereby resulting in apoptosis.
In this study, we demonstrate both a novel antiapoptotic role
for CIP2A in CML pathogenesis and a key role for BCL-XL in survival
of CML cell lines and in primary CD34+ cells from patients. These
results raise the possibility that inhibition of BCL-XL may be a
novel therapeutic option in CML, especially in patients refractory
to TKI therapy.
MATERIALS AND METHODS
Reagents and antibodies
Imatinib, nilotinib and dasatinib were from Selleck Chemicals (Houston, TX,
USA). ABT-737, ABT-199, A-1331852 and A-1210477 were kindly provided
by AbbVie (North Chicago, IL, USA). Antibodies against BIM, PUMA, BMF,
BIK, BAD, BCL-XL and BCL-w were from Cell Signaling Technology (Danvers,
MA, USA), GAPDH and MCL-1 from Santa Cruz Biotechnology (Santa Cruz,
1Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK and 2Department of Molecular and Clinical Pharmacology, University of Liverpool,
Liverpool, UK. Correspondence: Dr S Varadarajan, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Sherrington
Building, Ashton Street, Liverpool L69 3GE, UK.
E-mail: svar@liv.ac.uk
Received 28 August 2015; revised 10 February 2016; accepted 12 February 2016; accepted article preview online 29 February 2016
Leukemia (2016), 1–9
© 2016 Macmillan Publishers Limited All rights reserved 0887-6924/16
www.nature.com/leu
CA, USA), NOXA from Calbiochem (Darmstadt, Germany), BCL-2 from Dako
(Ely, UK), BAX and BAK from Millipore (Watford, UK), HRK from Aviva
Systems Biology (San Diego, CA, USA) and BID and BFL-1 were from Prof J
Borst (The Netherlands Cancer Institute, Amsterdam, The Netherlands).
All other reagents, unless mentioned otherwise, were from Sigma-Aldrich
(St Louis, MO, USA).
Patient cohort
The study was approved by the Liverpool Central Research Ethics
Committee; all 31 patients gave informed consent and were aged 18 or
over. All have been seen since original diagnosis of chronic phase CML
at our center and have been followed for at least 12 months (median
follow-up: 39 months). Patients’ characteristics are presented in
Supplementary Table S1.
Sample collection, preparation and cell culture
At diagnosis, mononuclear cells from chronic phase CML patients were
separated by density-dependent centrifugation (Lymphoprep Axis-Shield,
Oslo, Norway), washed in RPMI 1640 (BioSera, Uckﬁeld, UK) and
resuspended in 10% dimethyl sulfoxide/10% fetal calf serum (BioSera)/
RPMI at 4 °C and cryopreserved in liquid nitrogen. Wherever possible,
samples were enriched for CD34+ cells using the CliniMACS kit
(Miltenyi Biotec, Auburn, CA, USA). CD34+ cells were cultured using
StemSpan SFEMII media (Stemcell Technologies, Cambridge, UK). K562 and
KCL22 cells were cultured in RPMI 1640 supplemented with 10% fetal calf
serum and 5 mM L-glutamine.
BH3 proﬁling and ﬂow cytometry
BH3 proﬁling was carried out using BH3 peptides from New England
Peptide (Gardner, MA, USA) as previously described.25 Loss of mito-
chondrial membrane potential and apoptosis were quantiﬁed by ﬂow
cytometry as described.26 Patients with CIP2A levels ⩾ 7.3 mean
ﬂuorescence units by ﬂow cytometry were deﬁned as high CIP2A patients,
as every patient that progressed to BC had CIP2A47.3 mean ﬂuorescence
units.27 This cutoff value was derived using receiver operating character-
istics (ROC) curve analysis for the prediction of BC based on the diagnostic
CIP2A protein level; minimization of the Euclidian distance between the
receiver operating characteristics curve and the corner (0, 1) was the
criterion used. The optimal cutoff value produced an AUCROC = 0.902 (95%
CI: 0.832, 0.973).
siRNA knockdowns, immunoprecipitation and western blotting
Cells were reverse-transfected with 10 nM of BAK (s1880 and s1881),
BAX (s1888 and s1889), BIM (s195011), PUMA (pool of siRNAs), BMF (pool of
siRNAs), BIK (s1989 and s1990), HRK (s194952), BCL-XL (s1920), MCL-1
(s8583), BCL-w (s1924), BFL-1 (pool of siRNAs) from Life Technologies
(Paisley, UK), BID (SI02654568), NOXA (SI00129430), BAD (SI00299348),
BCL-2 (S100299411) from Qiagen (Manchester, UK) using Interferin
Figure 1. BH3 proﬁling and RNA interference implicate roles for BCL-2, BCL-XL and MCL-1 in TKI-induced apoptosis. (a) BH3 proﬁling in K562
cells was carried out using the speciﬁed concentrations of different BH3 peptides for 2 h. PUMA-2A was used as the control peptide.
(b) Dynamic BH3 proﬁling in K562 and KCL22 cells, exposed to increasing concentrations of imatinib for 16 h, was carried out using either
control peptide (bold continuous lines) or BIM peptide (dotted lines) at 1 μM for 2 h. (c) K562 and KCL22 cells, reverse-transfected with the
indicated siRNAs, were exposed for 48 h to dimethyl sulfoxide, imatinib (1 μM), nilotinib (50 nM) or dasatinib (3 nM) and apoptosis assessed by
phosphatidylserine (PS) externalization. Statistical analysis was conducted using one-way analysis of variance applying the Welch correction
and Dunnet’s two-sided multiple comparison test to compare the different treatments to the appropriate control peptide/ siRNA (*P⩽ 0.05,
**P⩽ 0.01, ***P⩽ 0.001). Error bars represent standard error of mean (s.e.m.) from three independent experiments.
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(Polyplus Transfection, NY, USA), according to the manufacturer's protocol
and processed 48 h after transfection. Immunoprecipitation and western
blotting were carried out according to the standard protocols.26
mRNA expression
Quantitative reverse transcription–PCR was performed using cDNA
from total leukocytes. Pre-designed TaqMan real-time PCR assays
were used for BCL2L11 (Hs00708019_s1), BCL2L1 (Hs00236329_m1), BID
(Hs00609632_m1), BBC3 (Hs00248075_m1), HRK (Hs02621354_s1) and BAD
(Hs00188930_m1) and GAPDH (Hs99999905_m1) (Life Technologies). PCR
was performed using a Stratagene MX3005P PCR machine (Agilent
Technologies, Folsom, CA, USA). In evaluating the mRNA expression data,
the comparative Ct method was used, with the 2−ΔΔCt formula to achieve
results for relative quantiﬁcation. A pool of cDNA from four normal
individuals was used as a calibrator and all samples were normalized to
GAPDH.
Statistical analysis
Statistical analysis was conducted using one-way analysis of variance
applying the Welch correction and Dunnet’s two-sided multiple compar-
ison test to compare the different treatments to the appropriate control
peptide/siRNA (*P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001). For continuous variables,
the Mann–Whitney U-test was used for comparisons between independent
samples. For categorical variables, Fisher’s exact test was used.
Progression-free survival functions were estimated by the Kaplan–Meier
estimator and the log-rank test was used for comparisons between groups.
Statistical analysis was performed using GraphPad Prism (GraphPad Prism
Software, Inc., La Jolla, CA, USA).
RESULTS
TKIs prime CML cell lines to undergo apoptosis
Since high levels of CIP2A contributed to imatinib resistance in
CML, we wished to understand the role of BCL-2 family members
in this resistance mechanism. Using BH3 proﬁling, a peptide-based
technique to determine BCL-2 family dependencies,25 we
observed extensive loss of mitochondrial membrane potential
(φm) in two CML cell lines, K562 and KCL22, following exposure to
increasing concentrations of different BH3 peptides (Figure 1a and
Supplementary Figure S1). Although all BH3-only activators
exhibited extensive mitochondrial depolarization, BH3-only sensi-
tizers demonstrated greater selectivity as demonstrated by a
concentration-dependent loss in φm following BMF, BAD and HRK,
but not NOXA (Figure 1a and Supplementary Figure S1). These
results suggested that the survival of these cells depended more
Figure 2. TKIs induce apoptosis in a BH3-dependent manner. (a, b) K562 and KCL22 cells, reverse-transfected with the indicated siRNAs, were
exposed for 48 h to dimethyl sulfoxide, imatinib (1 μM), nilotinib (50 nM) and dasatinib (3 nM) and apoptosis assessed by phosphatidylserine
(PS) externalization. Statistical analysis was conducted using one-way analysis of variance applying the Welch correction and Dunnet’s two-
sided multiple comparison test to compare the different siRNA transfections to their appropriate control siRNA in each treatment (*P⩽ 0.05,
**P⩽ 0.01, ***P⩽ 0.001). Error bars represent s.e.m. from three independent experiments.
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on BCL-2, BCL-XL and BCL-w, rather than on MCL-1 and BFL-1, as
NOXA was the only sensitizer among the list to speciﬁcally target
both MCL-1 and BFL-1 (Figure 1a and Supplementary Figure S1).9–11
In dynamic BH3 proﬁling studies,28 increasing concentrations of
TKIs resulted in a signiﬁcant loss of φm, only when the cells were
subsequently exposed to the BIM peptide, suggesting that TKIs
primed these cells to apoptosis and a combination therapy with
another apoptotic stimuli could facilitate rapid apoptosis in these
cells (Figure 1b and Supplementary Figure S2). Since our data
implicated speciﬁc members of the BCL-2 family in antagonizing
apoptosis, we performed RNA interference to silence the
expression of different BCL-2 family members to study their
effects on TKI-mediated apoptosis (Figure 1c). The concentrations
of TKIs used in these studies were determined from their
concentration–response curves (Supplementary Figure S3). Down-
regulation of BCL-XL and to some extent BCL-2 resulted in
apoptosis, suggesting that BCL-XL is a critical survival factor in
both CML cell lines (Figure 1c). Furthermore, downregulation of
BCL-XL, and to a lesser extent, BCL-2 and MCL-1, signiﬁcantly
potentiated TKI-mediated apoptosis in both K562 and KCL22
(Figure 1c), thus conﬁrming an important role for antiapoptotic
BCL-2 family members in TKI-mediated apoptosis.
TKIs induce apoptosis in a BH3-dependent manner
Exposure to TKIs caused a time-dependent decrease in the
expression levels of most anti- and proapoptotic BCL-2 family
members, with the notable exception of BAD, which was
signiﬁcantly upregulated (Supplementary Figure S4). To under-
stand the relative contribution of different proapoptotic BCL-2
members in TKI-mediated apoptosis, we silenced the expression
of BAX, BAK as well as BH3-only activators and sensitizers in K562
and KCL22 (Figure 2). Although all the proapoptotic effector and
activator proteins were critical for TKI-mediated apoptosis, a
selective dependence on HRK and BAD, but not NOXA, BMF or BIK
was observed in TKI-mediated apoptosis (Figure 2 and
Figure 4. High CIP2A expression levels correlate with an antiapop-
totic phenotype. mRNA expression for BIM, BID, PUMA, HRK, BAD and
BCL-XL in 31 newly diagnosed chronic phase CML patients stratiﬁed
by their diagnostic CIP2A status. A pool of four normal healthy
volunteers was used as a calibrator pool. Statistical analysis
was conducted using a Mann–Whitney U-test comparing high and
low CIP2A patients (**P⩽ 0.01). Error bars represent s.e.m.
Figure 3. Expression levels of the proapoptotic BH3-only proteins correlate with progression-free survival in CML patients. Progression-free
survival for patients treated with imatinib at initial diagnosis. PCR was performed using total leukocytes collected at initial diagnosis. Patients
were stratiﬁed into high and low expression groups according to the median mRNA expression for BIM, BID, PUMA, HRK and BAD and the
number of cases assessed presented below each graph. The log-rank test was used to determine the signiﬁcance between high and low
expressers.
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Supplementary Figure S4), thus implicating a regulatory role for
several BH3-only members in TKI-induced apoptosis.
Downregulation of proapoptotic BCL-2 family proteins is
associated with disease progression in imatinib-treated patients
To investigate a possible relationship between these BH3-only
proteins and clinical outcome, we compared the mRNA expression
levels of these proteins with progression-free survival of chronic
phase CML patients, treated with imatinib at diagnosis (Figure 3).
The median expression level for each gene was calculated and
patients were stratiﬁed as high or low relative to the median. Low
BIM expression was associated with an inferior progression-free
survival, whereas BID or BAD expression did not correlate with
clinical outcome (Figure 3). Low PUMA and HRK expression were
signiﬁcantly associated with disease progression to BC (P= 0.03;
Figure 3). In this study, four patients progressed to BC and this
disease progression was not associated with the presence of BCR-
ABL kinase domain mutations. Low expression of BIM, PUMA and
HRK was also associated with poor overall survival but this did not
reach signiﬁcance (data not shown). Moreover, 50% of patients
with low PUMA or HRK expression at diagnosis had progressed by
36 months (Figure 3). In addition, low diagnostic levels of BIM and
HRK were associated with a slower rate of deep molecular
response (MR5) during the ﬁrst three years of treatment (data not
shown).
CIP2A levels correlate with the balance between pro- and
antiapoptotic BCL-2 family proteins
Since CML disease progression correlates with high CIP2A
levels,5,29 as well as changes in expression levels of different
BCL-2 family members (Figure 3), we speculated whether CIP2A
levels could correlate with the expression levels of different BCL-2
family members. To investigate this possibility, we assessed mRNA
expression for BIM, BID, PUMA, HRK, BAD and BCL-XL in newly
diagnosed chronic phase CML patients. Expression levels of BIM,
PUMA and HRK were signiﬁcantly lower in high compared with low
CIP2A patients (Figure 4). A similar trend was observed for BID and
BAD expression but this did not reach statistical signiﬁcance
(Figure 4). In contrast, patients with high CIP2A levels expressed
high levels of BCL-XL, although this did not reach statistical
signiﬁcance (Figure 4). Taken together these results suggest that
CIP2A may exhibit its oncogenic activity by altering the balance of
pro- and antiapoptotic proteins resulting in an antiapoptotic
phenotype.
Figure 5. BCL-XL is a critical survival factor and regulates TKI-induced apoptosis in CML cell lines. (a) K562 and KCL22 cells were exposed for
24 h to the speciﬁed inhibitors and apoptosis assessed by phosphatidylserine (PS) externalization. (b) Immunoprecipitation of BCL-XL was
carried out in K562 cells, exposed to A-1331852 (100 nM) for 0–2 h, and the eluted complexes were immunoblotted for the indicated proteins.
The input cell lysates and the immunodepleted supernatant (labeled as Flow-through) were immunoblotted to check the efﬁciency of the
immunoprecipitation. BC represents beads control. (c) K562 cells, exposed for 1 h to 1 nM of ABT-199 or A-1331852, were further exposed in
the presence of the pretreated inhibitors to imatinib (1 μM), nilotinib (50 nM) or dasatinib (3 nM) for 24 h and apoptosis assessed. (d) Same as (b)
but the immunoprecipitation was carried out with antibodies against BCL-XL in K562 cells exposed to A-1331852 (1 nM) with or without
nilotinib (50 nM) for 24 h. Statistical analysis was conducted using one-way analysis of variance applying the Welch correction and Dunnet’s
two-sided multiple comparison test to compare the TKI treatments with the combination treatments of A-1331852, represented by the black
and gray histograms (*P⩽ 0.05). Error bars represent s.e.m. from three independent experiments.
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BCL-XL is a critical survival factor and antagonizes TKI-induced
apoptosis in CML cell lines
Since our initial data identiﬁed BCL-XL as a critical survival factor in
CML cell lines, we used a toolkit of selective BCL-2 family
inhibitors, comprising ABT-737 (BCL-2, BCL-XL and BCL-w-speciﬁc
inhibitor), ABT-199 (BCL-2-selective), A-1331852 (BCL-XL-speciﬁc)
and A-1210477 (MCL-1-selective) to further evaluate the role of
BCL-XL in CML cell survival. In both cell lines, A-1331852 was
extremely potent, inducing apoptosis at low nanomolar concen-
trations, whereas the other inhibitors failed to induce apoptosis
Figure 6. Inhibition of BCL-XL promotes rapid apoptosis in primary CML cells. (a, b) Diagnostic chronic phase CD34
+ cells from high CIP2A
patients were exposed to A-1331852 for 1 h (n= 3) and 4 h (n= 5) and apoptosis assessed. (c, d) Mononuclear cells (MNCs) from healthy
volunteers were exposed to A-1331852 for 1 h (n= 8) and 4 h (n = 6) and apoptosis assessed. (e) Diagnostic chronic phase CD34+ cells from
high CIP2A patients were exposed to imatinib (5 μM), dasatinib (150 nM) and nilotinib (5 μM) for 24 h followed by the addition of A-1331852
(10 nM) to the cells for a further 1 h (n= 5). Statistical analysis was conducted using a Mann–Whitney U-test and P-values speciﬁed, where
signiﬁcant. Error bars represent s.e.m.
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even at 100-fold higher concentrations (Figure 5a). A-1331852 was
efﬁcient in displacing both BIM and BAD from BCL-XL and
releasing them into the cytosol (Figure 5b). Furthermore,
A-1331852, but not ABT-199, was efﬁcacious in potentiating
TKI-mediated apoptosis for 2G TKIs (Figure 5c). A combination of
nilotinib and A-1331852 was more potent than either A-1331852
or nilotinib alone in displacing BIM from BCL-XL (Figure 5d), further
suggesting that A-1331852 can be effective in inducing apoptosis
in CML cell lines, either as a single agent or in combination
with TKIs.
A-1331852 exhibits remarkable potency both as a single agent
and in combination with TKIs in killing primary CD34+ CML cells
We next investigated the ability of A-1331852 to induce apoptosis
in primary CD34+ progenitor cells from high CIP2A patients. In
agreement with our data in CML cell lines, A-1331852 displayed
remarkable potency in inducing apoptosis in these cells at low
nanomolar concentrations as early as 1 h post-treatment
(Figure 6a). Prolonged exposure (4 h) resulted in improved
potency as A-1331852 induced extensive apoptosis (P= 0.002) at
concentrations as low as 1 nM in these cells (Figure 6b). Similar
results were observed in CD34+ progenitor cells from low CIP2A
patients (Supplementary Figure S5). In contrast, mononuclear cells
isolated from healthy volunteers generally remained insensitive to
the treatment (Figures 6c and d). This is particularly signiﬁcant as
clinically achievable concentrations of imatinib (5 μM), nilotinib
(5 μM) or dasatinib (150 nM) did not induce signiﬁcant apoptosis in
primary CD34+ cells after 4 h exposure (data not shown).
Even after 24 h exposure, none of these TKIs induced much if
any apoptosis above the high spontaneous apoptosis observed in
the progenitor cells (Figure 6e). However a subsequent and short
exposure to A-1331852 (1 h) following the initial 24 h exposure to
TKIs was sufﬁcient to induce enhanced apoptosis in these
CD34+ cells (P⩽ 0.01, Figure 6e). These data support the possibility
of targeting BCL-XL, as a novel and effective therapeutic strategy
in CML (Figure 7).
DISCUSSION
High expression of CIP2A contributes to imatinib resistance in CML
and is a strong prospective predictor of subsequent development
of BC in imatinib-treated patients.5 However the mechanism(s) by
which CIP2A increases the risk of disease progression is poorly
understood. In this study, we have identiﬁed several proapoptotic
BCL-2 family members to be critical in TKI-mediated apoptosis
(Figures 1 and 2). These ﬁndings also extended to CML patients, as
decreased expression of speciﬁc proapoptotic BH3-only members
PUMA, HRK and possibly BIM correlated with disease progression
in CML patients (Figure 3). To our knowledge, this is the ﬁrst study
to link several proapoptotic BCL-2 family members to progression-
free survival in imatinib-treated CML patients. We show that high
CIP2A expression levels correspond to low expression of speciﬁc
BH3-only proteins, BIM, PUMA and HRK, and an increase in the
expression of BCL-XL (Figure 4), highly characteristic of an
antiapoptotic phenotype.
Recently, we have shown that administration of 2G TKIs, such as
nilotinib and dasatinib, can overcome high CIP2A and prevent
disease progression.5,27 However, this is not without worrying side
effects, as dasatinib has a 25% risk of pleural effusion within ~ 3
years and nilotinib therapy is associated with hyperglycemia in
some patients and a dose-related (8–10%) risk of myocardial
infarction, cerebrovascular event or peripheral arterial occlusive
event by 6 years.30,31 This necessitates research into possible
alternate therapeutic strategies. In this study, using a BCL-XL-
speciﬁc inhibitor, A-1331852,23 we demonstrate for the ﬁrst time,
an effective therapeutic option for CML patients with high CIP2A
expression levels. A-1331852 displayed remarkable potency, both
as a single agent and in combination with TKIs, to induce
apoptosis in cell lines and in progenitor CD34+ primary cells
(Figures 5 and 6) demonstrating the critical importance of BCL-XL
in the survival of CML cells. Although BCL-XL has been associated
with disease progression,12,19,32–34 this is the ﬁrst study that
demonstrates a novel antiapoptotic role for CIP2A in CML
pathogenesis and how this can be overcome by selectively
targeting BCL-XL. This therapeutic option appears particularly
promising because the CD34+ progenitor cells were highly
sensitive to nanomolar concentrations of A-1331852 but
Figure 7. Selective inhibition of BCL-XL overcomes CIP2A-mediated regulation of BCL-2 family members and disease progression in CML.
The links that we have established/conﬁrmed in this study are presented as bold lines whereas the dashed lines represent ﬁndings from
literature. (a) The constitutively active kinase activity of BCR-ABL, antagonized by TKIs, results in phosphorylation of STAT5. (b) p-STAT5 induces
the transcription of BCL-XL. (c) BCL-XL sequesters and inhibits BH3-only proteins. (d) This antiapoptotic activity is abolished by A-1331852.
(e) Failure to achieve effective apoptosis results in disease progression. (f ) High levels of CIP2A correlate with imatinib resistance in CML
patients. (g) This can be overcome by second generation (2G) TKIs. (h) CIP2A expression levels correlate with an antiapoptotic phenotype
characterized by changes in the balance between the pro- and antiapoptotic BCL-2 family members, thus conferring resistance to TKI therapy
in CML. The precise mechanisms by which high CIP2A correlates with the antiapoptotic phenotype is unknown and hence marked with a ‘?’
(i) Selective inhibition of BCL-XL induces rapid apoptosis in CML cells, thus providing a novel and promising therapeutic option.
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insensitive to even prolonged exposure of the TKIs (Figure 6). This
observation is in agreement with previous studies demonstrating
a BCL-XL dependence of stem cell survival for human embryonic
stem cells as well as non-small-cell lung cancer cells.35,36 Thus,
targeting BCL-XL potentially offers great therapeutic beneﬁts in
CML, especially due to the insensitivity of quiescent CD34+
progenitor CML cells to imatinib, which is a major factor in the
recurrence of the disease on discontinuation of therapy,17,37
although it will be necessary to overcome potential toxicities, such
as thrombocytopenia, associated with BCL-XL inhibition.
22,38
In summary, we clearly demonstrate that high CIP2A corre-
sponds to an antiapoptotic phenotype, which may contribute to
the poor prognosis of CML patients. We have also shown that this
antiapoptotic phenotype can be overcome in CML by targeting
BCL-XL, thus identifying an effective therapeutic option for
CML patients with high expression levels of CIP2A (Figure 7). As
high CIP2A levels are also implicated in disease progression in
acute myeloid leukemia, breast, bladder, cervical, colon, hepato-
cellular and lung cancer,39–46 it will be of interest to ascertain if
these tumors also exhibit an antiapoptotic phenotype. Targeting
this antiapoptotic phenotype with selective BCL-2 family antago-
nists may offer novel therapeutic approaches to these
malignancies.
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